Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jul 24, 2026
Reporting period
Not applicable
Filed with the SEC
Jul 28, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000313143-26-000099
Filed / recorded
Jul 28, 2026, 8:49 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
HAEMONETICS CORP
Issuer CIK
313143
Ticker
HAE
Reporting person
Robert E Abernathy
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jul 24, 2026
Transaction code
A
Shares / units
2,538
Acquired / disposed
Acquired (A)
Shares owned after
27,519
Ownership form
Direct
Amendment
No
Footnotes from the filing
The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.